Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

[1]  P. Schellhammer,et al.  Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC) , 2005 .

[2]  D. McNeel,et al.  Immune-based therapies for prostate cancer. , 2005, Immunology letters.

[3]  R. Kiessling,et al.  A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer , 2004, British Journal of Cancer.

[4]  J. Manola,et al.  Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. McNeel,et al.  DNA vaccine encoding a prostate-specific protein elicits CD8 T cell immunity and tissue-specific inflammation , 2004 .

[6]  A. D'Amico,et al.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[8]  E. Engleman,et al.  Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1 , 2001, The Journal of Immunology.

[9]  D. McNeel,et al.  Identification of T helper epitopes from prostatic acid phosphatase. , 2001, Cancer research.

[10]  G. Yousef,et al.  Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. , 2001, Genomics.

[11]  M. Peshwa,et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Vessella,et al.  Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. , 2000, The Journal of urology.

[13]  J. Buckner,et al.  Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  T. Whiteside,et al.  Generation of PSA‐reactive effector cells after vaccination with a PSA‐based vaccine in patients with prostate cancer , 2000, The Prostate.

[15]  R. Purcell,et al.  Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[16]  H. Ragde,et al.  Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment , 1999, The Prostate.

[17]  M. Peshwa,et al.  Induction of prostate tumor‐specific CD8+ cytotoxic T‐lymphocytes in vitro using antigen‐presenting cells pulsed with prostatic acid phosphatase peptide , 1998, The Prostate.

[18]  E. Engleman,et al.  Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. , 1997, Journal of immunology.

[19]  O. Jänne,et al.  Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatases. , 1990, Gene.

[20]  P. Henttu,et al.  High degree of homology between primary structure of human lysosomal acid phosphatase and human prostatic acid phosphatase. , 1989, Biological chemistry Hoppe-Seyler.

[21]  J. Trudell,et al.  Comparative Toxicity of Halothane, Isoflurane, Hypoxia, and Phenobarbital Induction in Monolayer Cultures of Rat Hepatocytes , 1988, Anesthesiology.

[22]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[23]  W. Ellis,et al.  The Prostate 47:222^229 (2001) Naturally Occurring Prostate Cancer Antigen- Specific T Cell Responses of aTh1Phenotype Can Be Detectedin Patients With Prostate Cancer , 2022 .